Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia

PHASE3CompletedINTERVENTIONAL
Enrollment

252

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

November 30, 2013

Study Completion Date

December 31, 2013

Conditions
Schizophrenia
Interventions
DRUG

Aripiprazole

Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)

DRUG

Aripiprazole

Aripiprazole (10-mg, 15-mg, 20-mg, 25-mg or 30-mg)

Trial Locations (52)

110

Study Site, Taipei

333

Study Site, Taoyuan

833

Study Site, Kaohsiung County

1000

Study Site, Manila

1553

Study Site, Mandaluyong

4114

Study Site, Dasmariñas

5000

Study Site, Iloilo City

8000

Study Site, Bajada

27517

Study Site, Chapel Hill

30308

Study Site, Atlanta

30450

Study Site, Ipoh

33155

Study Site, Miami

33166

Study Site, Miami Springs

48302

Study Site, Bloomfield Hills

50603

Study Site, Kuala Lumpur

68100

Study Site, Batu Caves

81200

Study Site, Johor Bahru

90241

Study Site, Downy

91204

Study Site, Glendale

98011

Study Site, Bothell

124617

Study Site, Moscow

127083

Study Site, Moscow

150003

Study Site, Yaroslavl

163530

Study Site, Arkhangelsk

185001

Study Site, Petrozavodsk

190005

Study Site, Saint Petersburg

197376

Study Site, Saint Petersburg

200620

Study Site, Craiova

221005

Study Site, Varanasi

226003

Study Site, Lucknow

300239

Study Site, Timișoara

357034

Study Site, Tonnelnyi Township

380008

Study Site, Maninagar, Ahmedabad

399313

Study Site, Lipetsk

400084

Study Site, Cluj-Napoca

410028

Study Site, Saratov

420061

Study Site, Kazan'

431005

Study Site, Aurangabad

442004

Study Site, Wardha

460000

Study Site, Orenburg

492001

Study Site, Raipur

520002

Study Site, Vijayawada

522001

Study Site, Guntur

530017

Study Site, Visakhapatnam

600003

Study Site, Chennai

603155

Study Site, Nizhny Novgorod

620030

Study Site, Yekaterinburg

625020

Study Site, Madurai

630091

Study Site, Novosibirsk

634014

Study Site, Tomsk

700282

Study Site, Iași

041914

Study Site, Bucharest

All Listed Sponsors
lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT01149655 - Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia | Biotech Hunter | Biotech Hunter